Cor et Vasa 2023, 65(5):729-734

Peter Bala, b, c, Slavomr Rokona, Adam Whitleya, d a Division of Vascular Surgery, Third Faculty of Medicine, Charles University and University Hospital Krlovsk Vinohrady, Prague, Czech Republic b Cardiocentre, Third Faculty of Medicine, Charles University, Prague, Czech Republic c Department of Vascular Surgery, National Institute of Cardiovascular Diseases, Bratislava, Slovak Republic d Department of Anatomy, Second Faculty of Medicine, Charles University, Prague, Czech Republic

vod: Clem tto studie bylo porovnat dva systmy uzavrn il kyanoakryltovm lepidlem, VenaSeal™ a VariClose®, v lb povrchov iln insuficience.

Metody: Byla provedena retrospektivn analza pacient lench od dubna 2018 do dubna 2022 kyanoakryltovmi lepidly pro insuficienci povrchovch il dolnch konetin v jednom centru.

Vsledky: Systm VariClose® byl pouit u 27 pacient (30 il) a systm VenaSeal™ u 97 pacient (125 il). Medin sledovn pacient lench systmy VariClose® a VenaSeal™ dosahoval 267 (IQR 223) a 201 (IQR 280) dn. Po roce dolo k rekanalizaci u 11 il lench systmem VariClose® a u 5 il lench systmem VenaSeal™. Mra okluze odhadnut Kaplanovou-Meierovou metodou v 30, 90, 180 a 360 dnech inila pro ly len systmem VariClose® 100 %, 96 %, 83 % a 42 % a pro ly len systmem VenaSeal™ 100 %, 98 %, 96 % a 91 % (p < 0,01).

Zvr: Systm VenaSeal™ ml vznamn lep mru okluze ne systm VariClose®. © 2023, KS.

Klov slova: Keov ly, Kyanoakrylt, VariClose®, VenaSeal™, iln nedostatenost

Bal P, Rokon S, Whitley A. Comparison of cyanoacrylate agents VariClose® and VenaSeal™ in the treatment of insufficient saphenous veins. Cor Vasa. 2023;65(5):729-734.